SARS-CoV-2 Antibody Response among Women Infected during Pregnancy

Abstract

Objectives Novel coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) virus has been declared a pandemic by the World Health Organization as of March 11, 2020. Pregnant women naturally have a reduced immune system due to immunological changes and decreased lung capacity due to respiratory adaptations, making them more susceptible to coronavirus complications. Within the Mount Sinai Health system, more than 15,000 deliveries are performed annually. We began to care for pregnant women with known COVID-19 infections in late March of 2020. In early April 2020, a policy was implemented to perform universal COVID-19 testing for all women planning to deliver within the Mount Sinai Health system. We examined the antibody response of postpartum women who delivered at Mount Sinai Hospital with a SARS-CoV-2 infection between the study intervals during March 15, 2020, through April 30, 2020.

Study Design This was a prospective observational study examining the immune response of pregnant women who delivered at Mount Sinai Hospital with a polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection. Women with a SARS-CoV-2 infection were contacted via phone to discuss participation in the study. Patients who consented were scheduled for a phlebotomy visit to assess their antibody titer levels to COVID-19. The COVID-19 enzyme-linked immunosorbent assay (ELISA) immunoglobulin (Ig)-G antibody test was used to evaluate the patients' antibody titers. The assay detects IgG antibodies for the detection of IgG seroconversion in patients following a known recent SARS-CoV-2 infection.

Results A total of 120 patients were identified with a documented SARS-CoV-2 infection who delivered within the prespecified time frame. Of those patients, 25 women agreed to participate and were included. Of them, 64.00% were Caucasian with a mean age of 35 years. The mean body mass index (BMI) was 30 kg/m² and the majority of patients had commercial insurance (88.00%). The majority of women were asymptomatic for COVID-19 at the time of admission (80.00%) and the average gestational age of delivery and diagnosis of COVID-19 was 39 weeks' gestation. The later the gestational age at the time of diagnosis, the lower the antibody titer response. When examining the interval from diagnosis to antibody titer analysis, patients with the highest titers (2,880) tended to have a shorter interval between their COVID-19 diagnosis and the time at which the titer level was drawn. Patients with symptoms on admission had similar antibody titer levels when compared with women who were asymptomatic.

Conclusion The antibody response among women infected with COVID-19 during pregnancy appears to be greater when the patients are diagnosed at an earlier gestational age.

Key Points

• COVID-19 antibody status appears to be greater when diagnosed at an earlier gestational age.

• Asymptomatic and symptomatic pregnant women had similar antibody responses.

• Patients with the highest titers tended to have a shorter interval between their COVID-19 diagnoses.

Keywords

SARS-CoV-2 - COVID-19 - antibody response to COVID-19 infection - COVID-19 antibody titers in the peripartum period - SARS-CoV-2 IgG ELISA - COVID-19 in pregnancy

Condensation

The antibody response among women infected with COVID-19 during pregnancy appears to be greater when diagnosed at earlier gestational ages.

Publication History

Received: 18 May 2021

Accepted: 06 October 2021

Article published online:
12 November 2021

• References

• 1 Ellington S, Strid P, Tong VT. et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-June 7, 2020. Morb Mortal Wkly Rep 2020; 69 (25) 769-775
• 2 Morelli S, Mandal M, Goldsmith LT, Kashani BN, Ponzio NM. The maternal immune system during pregnancy and its influence on fetal development. Res Rep Biol 2015; 2015 (06) 171-189
• 3 Lau EHY, Tsang OTY, Hui DSC. et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 2021; 12 (01) 63
• 4 Dustin D, Flannery D. (2021, January 29). Assessment of maternal and neonatal cord blood sars-cov-2 antibodies and placental transfer ratios. Accessed February 21, 2021 at: https://jamanetwork.com/journals/jamapediatrics/fullarticle/2775945
• 5 Krammer F, Srivastava K, Team T, Simon V. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of sars-cov-2 mrna vaccine. Accessed February 21, 2021 at: https://www.medrxiv.org/content/10.1101/2021.01.29.21250653v1
• 6 Amanat F, Stadlbauer D, Strohmeier S. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med 2020; 26 (07) 1033-1036
• 7 Amanat F, Meade P, Strohmeier S, Krammer F. Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model. Emerg Microbes Infect 2019; 8 (01) 155-168
• 8 Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection during pregnancy: Report of two cases & review of the literature. J Microbiol Immunol Infect 2019; 52 (03) 501-503
• 9 New York State Department of Health. Coronavirus disease 2019 (COVID-19). https://covid19tracker.health.ny.gov/views/NYSCOVID19-Tracker/NYSDOHCOVID-19TrackerMap?%3Aembed=yes&%3Atoolbar=no&%3Atabs=n. Accessed February 21, 2021
• 10 Bianco A, Buckley AB, Overbey J. et al. Testing of patients and support persons for coronavirus disease 2019 (COVID-19) infection before scheduled deliveries. Obstet Gynecol 2020; 136 (02) 283-287